Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04391894 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
A Phase 2 study of Dry Eye, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 718
- Enrollment target
- 20
- Study locations
NCT04391894 is a Phase 2 study of Dry Eye that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 718 participants, above the 78-participant average among 41 other Dry Eye trials with a reported enrollment target (821% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT04391894, a Phase 2 study of Dry Eye, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 718 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study was planned to be conducted in 2 parts: Part 1 to determine the efficacy and safety of ECF843 vs vehicle, followed by Part 2 with additional exploratory assessments of ECF843 vs Vehicle. Both parts of the study included a double-masked study design, with randomization stratified for subjects with Sjogren's Syndrome.
Conditions Studied
Interventions
- DRUG ECF843
- OTHER ECF843 vehicle
Study Locations (20)
California
- Milton Hom OD - Azusa
- Orange County Opthamology Med Grp - Garden Grove
- Dr Kent Small - Glendale
- Global Research Management - Glendale
- United Medical Research Institute - Inglewood
- Harvard Eye Associates - Laguna Hills
- North Valley Eye Medical Group - Mission Hills
- The Eye Research Foundation - Newport Beach
- North Bay Eye Associates Inc - Petaluma
- Martel Eye Medical Group - Rancho Cordova
- Sierra Clin Trials Rsch Org - Santa Ana
Florida
- Advanced Research LLC - Deerfield Beach
- Pinnacle Research Institute - Fort Lauderdale
- Eye Associates Of Fort Myers - Fort Myers
- Lee Shettle Eye & Hearing - Largo
- Mid Florida Eye Center Pa - Mt. Dora
Arizona
- Arizona Eye Center - Chandler
- Carrot Eye Center - Mesa
- Phoenix Eye Care and Dry Eye Ctr - Phoenix
Colorado
- Vision Institute - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 718 participants |
| Start Date | 2020-10-06 |
| Est. Completion | 2021-05-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04391894
The ClinicalTrials.gov registry entry for NCT04391894 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 718 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 78-participant average among 41 other Dry Eye trials with a reported enrollment target (821% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which ECF843 is the first listed.
NCT04391894 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04391894 about?
NCT04391894 is a clinical study titled "A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease". The study was planned to be conducted in 2 parts: Part 1 to determine the efficacy and safety of ECF843 vs vehicle, followed by Part 2 with additional exploratory assessments of ECF843 vs Vehicle. Both parts of the study included a double-masked study design, with randomization stratified for subjec...
What is the current status of trial NCT04391894?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 718 participants. The study started on 2020-10-06. Estimated completion is 2021-05-13.
What conditions does trial NCT04391894 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT04391894?
The interventions under investigation include: ECF843 (DRUG), ECF843 vehicle (OTHER).
Who is sponsoring clinical trial NCT04391894?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04391894 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
Phase 2b Controlled Study of Dosing Techniques - Part B
ACTIVE NOT RECRUITING · Phase 2
-
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
COMPLETED · Phase 2
-
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
COMPLETED · Phase 2
-
Treatment of Patients With Blepharitis and Facial Rosacea
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.